According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best drug store stocks to buy right now are:
1. High Tide (NASDAQ:HITI)
High Tide (NASDAQ:HITI) is the #1 top pharmaceutical retailer stock out of 7 with a Zen Rating of C. Stocks with a rating of C have had an average return of +7.53% per year.
Learn more.
The Component Grade breakdown for High Tide (NASDAQ:HITI) is: Value: C, Growth: C, Momentum: C, Sentiment: C, Safety: D, Financials: C, and AI: C.
High Tide (NASDAQ:HITI) has a Due Diligence Score of 43, which is 22 points higher than the pharmaceutical retailer industry average of 21.
HITI passed 14 out of 33 due diligence checks and has strong fundamentals. High Tide has seen its stock return 80.83% over the past year, overperforming other pharmaceutical retailer stocks by 99 percentage points.
High Tide has an average 1 year
price target of $5.00, an upside of 43.27% from High Tide's current stock price of $3.49.
High Tide stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering High Tide, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Wellgistics Health (NASDAQ:WGRX)
The Component Grade breakdown for Wellgistics Health (NASDAQ:WGRX) is: Value: D, Growth: C, Momentum: C, Sentiment: C, Safety: D, Financials: F, and AI: C.
Wellgistics Health (NASDAQ:WGRX) has a Due Diligence Score of 4, which is -17 points lower than the pharmaceutical retailer industry average of 21.
WGRX passed 1 out of 33 due diligence checks and has weak fundamentals.
3. Petmed Express (NASDAQ:PETS)
The Component Grade breakdown for Petmed Express (NASDAQ:PETS) is: Value: C, Growth: C, Momentum: D, Sentiment: C, Safety: C, Financials: C, and AI: C.
Petmed Express (NASDAQ:PETS) has a Due Diligence Score of 22, which is 1 points higher than the pharmaceutical retailer industry average of 21. Although this number is above the industry average, our proven quant model rates PETS as a "D".
PETS passed 8 out of 38 due diligence checks and has weak fundamentals. Petmed Express has seen its stock lose -1.61% over the past year, overperforming other pharmaceutical retailer stocks by 17 percentage points.
Petmed Express has an average 1 year
price target of $3.20, an upside of 4.92% from Petmed Express's current stock price of $3.05.
Petmed Express stock has a consensus Strong Sell recommendation according to Wall Street analysts. Of the 1 analyst covering Petmed Express, 0% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 100% have issued a Strong Sell.